Boehringer Ingelheim
Boehringer Ingelheim, a leading global pharmaceutical company, is headquartered in Ingelheim am Rhein, Germany. Founded in 1885, the company has established a strong presence in the healthcare industry, focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a commitment to innovation, Boehringer Ingelheim is renowned for its core products, including treatments for respiratory diseases, cardiovascular conditions, and diabetes management. The company’s dedication to research and development has led to significant milestones, positioning it among the top pharmaceutical firms worldwide. Notable achievements include a robust pipeline of novel therapies and a strong market presence in Europe, North America, and Asia. Boehringer Ingelheim continues to enhance its reputation through its unique approach to healthcare solutions, prioritising patient needs and sustainable practices.
DitchCarbon Score
How does Boehringer Ingelheim's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim's score of 27 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim's reported carbon emissions
In 2023, Boehringer Ingelheim reported global carbon emissions of approximately 295,000,000 kg CO2e for Scope 1 and 66,000,000 kg CO2e for Scope 2. The company has demonstrated a commitment to reducing its carbon footprint, with significant reductions observed over the years. For instance, in 2022, their emissions were about 111,600,000 kg CO2e, indicating a substantial decrease from previous years. Boehringer Ingelheim's emissions data reveals a consistent focus on managing Scope 1 and Scope 2 emissions, with no reported Scope 3 emissions data for 2023. The company has not set specific reduction targets under the Science Based Targets initiative (SBTi) or other formal climate pledges, but their ongoing efforts reflect a commitment to sustainability and carbon reduction. Overall, Boehringer Ingelheim's emissions trajectory shows a positive trend towards minimising their environmental impact, aligning with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 289,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 273,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 3,801,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boehringer Ingelheim is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
